Vivanza Biosciences Limited reported a return to profitability in Q1FY26, posting a standalone net profit of ₹14.51 lakh compared to a net loss of ₹26.61 lakh in the previous quarter. The company’s revenue from operations rose 16.9% year-on-year to ₹914.09 lakh, signaling improved operational momentum. This turnaround is significant for shareholders as it marks a shift from consecutive losses in the prior period, stabilizing earnings for the current fiscal start.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 7, 2026, at its meeting held at the registered office in Ahmedabad. The results were reviewed by Shivam Soni & Co., the statutory auditors, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The limited review report confirmed that the financial statements present true and fair views without material misstatement.

Financial Performance Highlights

The company’s top-line growth was supported by higher revenue from operations, which stood at ₹914.09 lakh in Q1FY26, up from ₹782.06 lakh in the same quarter last year. On a consolidated basis, revenue reached ₹928.97 lakh, an increase of 4.1% year-on-year from ₹893.92 lakh. Other income contributed ₹37.28 lakh to the total income, a substantial rise from ₹1.74 lakh in Q1FY25.

On the cost side, purchase of stock-in-trade amounted to ₹932.73 lakh, while employee benefits expense was ₹9.56 lakh. Finance costs remained relatively stable at ₹10.62 lakh. The profit before tax stood at ₹18.08 lakh, against a loss of ₹12.32 lakh in the previous quarter.

What the Numbers Show

A key observation from the filing is the significant contribution of other income to the bottom line. While revenue grew steadily, other income jumped to ₹37.28 lakh from just ₹0.77 lakh in the previous quarter and ₹1.74 lakh year-on-year. This non-operational income component played a crucial role in driving the net profit turnaround, as operational margins remain thin with total expenses closely tracking total income. Investors should monitor whether this other income is recurring or one-off in nature for future quarters.

The company operates in three segments: Pharmaceuticals, Agro, and Film-related activities. The consolidated results include the subsidiary Vivanza Lifesciences Private Limited. Earnings per share (basic and diluted) were ₹0.04 for the quarter, compared to a loss of ₹0.07 per share in Q4FY25.

Vivanza Biosciences Limited has filed its audited financial results for the quarter and year ended March 31, 2026, confirming the statutory auditors have issued an unmodified opinion on the report. The disclosure ensures compliance with regulatory requirements regarding the timely announcement of financial performance.

The audit was conducted by M/S. Shivam Soni & Co, Chartered Accountants, based in Ahmedabad. The firm holds Firm Registration Number (FRN) 152477W. An unmodified opinion indicates that the financial statements present a true and fair view of the company's financial position and performance in accordance with applicable accounting standards.

The filing was submitted to BSE Limited pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates the declaration of audited financial results within a specified timeframe. The company's scrip code on the exchange is 530057.

The document was signed by Jayendra Amichand Mehta, Managing Director of Vivanza Biosciences Limited. The digital signature was verified on July 11, 2026.